Kornimate/medical-research-clean huggingface dataset:
exposed hypersensitive dentin treated with fluoride iontophoresis with remineralizing agents

Conditions: Dentin Hypersensitivity

Summary: the goal of this clinical trial is to learn if the application of fluoride works to treat patients suffering from dentin hypersensitivity. it will also learn about the safety of using fluoride iontophoresis with acidulated phosphate fluoride gel. the main questions it aims to answer are: does the remineralizing agent have the ability to decrease dentin sensitivity? researchers will compare fluoride iontophoresis with acidulated phosphate fluoride gel , casein phosphopeptides-amorphus calcium phosphate (cpp-acp), nano-hydroxyapptite (nhap) and -active glass in decreasing dentin hypersensitivity . participants will: * application of remineralizing agent every 3 months * visit the dental clinic once every 3 months for checkups and tests

assess the efficacy of fluoride iontophoresis in remineralization in comparison with other ingredients.

Eligibility criteria:
inclusion criteria: * patients within 35-60 years of age. * each patient has 4 or more exposed roots of posterior teeth having sensitivity. * good oral hygiene. * patients who will agree to the consent and will commit to the follow-up period. * patients will follow instructions during study time. * teeth that were vital. exclusion criteria: * patients with any systemic disease that may affect normal healing. * patient with bad oral hygiene, high caries index and high plaque index * patients participating in more than 1 dental study. * active carious lesions. * intrinsic and extrinsic stains. * any previous filling of selected teeth. * cracked and malformed teeth.

Keywords: hypersinsitivity flouride iontophoresis
comparison of the cosmetic outcome of hypofractionated versus normofractionated imrt in treatment of breast cancer

Conditions: Tumors; Breast Cancer

Summary: several multicenter studies have shown the equivalence of hypofractionated radiotherapy and normofractionated radiotherapy after breast-conserving surgery. however, the treatment in these studies was carried out with conventional techniques and not with the modern imrt. also the evaluation of quality of life and cosmetic outcome were not standardized. this study is a two-arm prospective study comparing normofractionated and hypofractionated radiotherapy in patients with breast cancer using tangential imrt techniques. the primary endpoints are acute and chronic cosmetic breast changes. the secondary endpoint is the patients' quality of life. patients to be included are breast cancer 60 years old patients or older with tumour stages ptis-pt3, pn0-pn1a, m0 after breast-conserving surgery. patients with right sided breast cancer are stratified to receive a hypofractionated treatment course (40.05 / 2.67gy in 15 fractions) and the left sided breast cancer a normofractionated irradiation (50/2gy in 25 fractions). in both arms, patients between 60-69 years are to receive a boost (16 gy / 2gy). in both groups, a tangential intensity-modulated radiation technique aiming to achieve optimal dose homogeneity is applied. since higher single radiation dose to the heart can lead to higher morbidity and/or mortality, patient stratification according to the diseased side was adopted where the left-sided breast cancer patients would receive normofractionated 2gy single dose. therefore there is no randomization. for classification and grading of adverse cosmetic events, the "common toxicity criteria (ctc-ae v3.0) and the recognized lent-soma scores are to be regularly documented. quality of life is to be documented with two standardized, validated questionnaires "qlq c30 and br23" of the eortc (european organization for research and treatment of cancer). the questionnaires are to be filled by the patients themselves at different time points during the study period. a sum of grade iii fibrosis, grade iii telangiectasia and grade ii hyperpigmentation of around 20% is expected after 2 years. therefore, calculation of the required number of cases based on an alpha of 0.05 and a power of 80% with a maximal tolerable toxicity difference of 15% within 2 years results in the need for recruiting 226 patients (113 in each arm) (non-inferiority of hypofractionated therapy).


Eligibility criteria:
inclusion criteria: * histologically confirmed invasive or in situ breast cancer, tumor stage ptis-pt3, pn0-1a, m0 * age ≥ 60 years * signed informed consent from the patient exclusion criteria: * stage pn1b-pn3, pt4 and / or m1 * incomplete surgical resection * after mastectomy of the ipsilateral or contralateral breast * breast reconstruction with implant or expander insert * bilateral breast cancer * lack of compliance or consent * indications for irradiation of the axillary, supraclavicular or parasternal lymph nodes

Keywords: intensity-modulated radiation therapy (imrt) breast cancer hypofractionation
centralized reading assessment of chronic cerebrospinal venous insufficiency (ccsvi) in patients with multiple sclerosis and other neurological diseases

Conditions: Clinically Isolated Syndrome (CIS); Multiple Sclerosis (MS); Other Neurological Disorders (OND); Healthy (HC)

Summary: this a retrospective, blinded trial in which collaborators in italy will review the doppler findings from the combined transcranial and extracranial venous doppler (ctevd) trial in an attempt to measure reproducibility.

this study will retrospectively investigate doppler images from the second phase of the ctevd trial. 1. to determine the prevalence of ccsvi in patients with ms, compared with the prevalence observed in a control population consisting of other neurological diseases (ond) patients and healthy controls (hc) by using blinded, controlled centralized ultrasound reading assessment of 5 venous haemodynamic (vh) ccsvi ccsvi doppler ultrasound (cdus) criteria. 2. to investigate whether prevalence of ccsvi is different between centralized and local cdus reading of 5 vh ccsvi cdus criteria. 3. to investigate the prevalence of ccsvi in patients with ms, compared with the prevalence observed in a control population consisting of ond patients and hc, when bidirectional flow in the intracranial veins and sinuses cdus criterion is not considered as part of vh ccsvi cdus criteria. 4. to determine whether prevalence of ccsvi in patients with ms, compared with the prevalence observed in a control population consisting of ond patients and hc differs when using cdus velocity and flow parameters in the internal jugular veins (ijvs) and vertebral veins (vvs). 5. to determine the reproducibility of vh criteria by using of centralized and local blinded, controlled cdus reading assessment.

Eligibility criteria:
inclusion criteria: * participation in the ctevd phase 2 study * available cdus exam * diagnosed with cis, ms, ond, or being a hc * fulfilling inclusion criteria from the ctevd study exclusion criteria: * not having an available cdus exam * diagnosed with radiologically isolated syndrome (ris) or neuromyelitis optic (nmo) * fulfilling exclusion criteria from the ctevd study
safety and accuracy study of regadenoson atropine combination for stress echocardiography in identification of coronary artery disease

Conditions: Coronary Artery Disease

Summary: purpose: the investigators plan to test a newly fda approved pharmacologic stress agent, regadenoson, in conjunction with atropine in the use of stress echocardiography for the diagnosis of coronary artery disease. the selective nature of regadenoson allows for its use in patients with contraindications to the currently used drug, adenosine, which is non-selective. furthermore, the proposed protocol can be completed faster and without radiation exposure than the current protocol with adenosine. design: this is a prospective study evaluating people with no prior diagnosis of coronary disease with a prior stress test and are scheduled for cardiac catheterization. patients who meet inclusion criteria will undergo regadenoson-atropine echocardiography protocol prior to their catheterization. the study will be interpreted by two independent readers blinded to the catheterization results. the sensitivity, specificity, positive and negative predictive values of the regadenoson-atropine study will be then be calculated using the coronary angiogram as a gold standard.


Eligibility criteria:
inclusion criteria: 1. age \> 18 years old 2. able to provide consent 3. scheduled for cardiac catheterization either with or without a prior functional stress imaging study exclusion criteria: 1. any history of acute myocardial infarction, prior pci in last 3 months, bypass surgery, 2. history of greater than first degree av block, sick sinus syndrome in patients 3. patients with a pacemaker/lbbb 4. history on uncontrolled arrhythmias 5. patients with significant pulmonary disease, known or suspected bronchoconstrictive or bronchospastic lung disease or other hypersensitivity to adenosine 6. history of cardiac transplantation, hypertrophic cardiomyopathy, acute myocarditis or pericarditis, severe valvular heart disease 7. hemodynamically unstable patients 8. dipyridamole use within 30 hours, consumption of methylxanthines (e.g., tea, coffee, caffeinated soft drinks, chocolate, or cocoa) within 12 hours, or use of sublingual nitroglycerin within 2 hours 9. history of glaucoma or obstructive uropathy 10. allergy or hypersensitivity to atropine 11. participation in another investigational drug study within 1 month or participation in any previous regadenoson trial 12. pregnancy, breast feeding, or not using an acceptable method of birth control (if premenopausal) 13. . history of end-stage renal disease on hemodialysis or peritoneal dialysis

Keywords: coronary artery disease stress echocardiography regadenoson atropine coronary angiogram
effect of gastric bypass surgery on pancreatic islets and incretin function

Conditions: Obesity

Summary: the study aims at describing the acute and subacute changes after roux-en-y (rygb) gastric bypass in insulin secretion from the beta cell and glucagon secretion from the alpha cell as well as the stimulatory effect of the incretins on the pancreatic islets. rygb is a bariatric procedure that changes the gastrointestinal anatomy and has been demonstrated to cause remission of type 2 diabetes shortly after the operation, before any significant weight loss. the altered transit of nutrient through the gastrointestinal tract after the operation is thought to play a key role in this remission and studies have shown significant changes in the secretion of gut hormones, namely the incretin hormone glucagon-like peptide-1 (glp-1). however it is unknown whether the secretory function of the pancreatic islets as well as the stimulatory effect of the incretin hormones is changes postoperatively.


Eligibility criteria:
inclusion criteria: * normal glucose tolerance * age \> 18 years * bmi \> 40 or \> 35 if combined with hypertension or obstructive sleep apnoea * caucasian * normal hemoglobinaemia * signed informed consent exclusion criteria: * major psychiatric disorder * alcohol or drug abuse * major hearth or pulmonary disease * previous major abdominal disease (e.g. peritonitis, large hernia) * pregnancy/lactation * treatment with glp-1 analogs

Keywords: obesity roux-en-y gastric bypass incretin hormones beta cell function
the efficacy and safty of fmt in patients with cid

Conditions: Insomnia Chronic; Fecal Microbiota Transplantation; Sleep Disorder; Depression; Anxiety; Cognitive Impairment

Summary: this clinical trial aims to learn about the efficacy of fecal microbiota transplantation in patients with chronic insomnia disorder. the main question\[s\] it aims to answer is: • effectiveness of the fmt oral capsule route for patients with chronic insomnia participants in the intervention group will be given fmt by boral capsule pathway, and in the control group, they will be given the same appearance capsules containing starch. researchers will compare the sleep status(psqi and psg)of the patients in both groups.


Eligibility criteria:
inclusion criteria: 1. diagnosed cid by dsm-5 2. 18-60 years old24 3. body mass index (bmi) within the range of 18-24 kg/m² 4. no other pharmacologic treatment in the last month or at the stable maintenance stage (stable dose for more than two months) exclusion criteria: 1. currently pregnant, planning pregnancy shortly, or breastfeeding 2. undergoing or recently received immunosuppressive therapy, or severe immunosuppression (neutrophil count \<1500 cells/mm³, lymphocyte count \<500 cells/mm³) 3. diagnosis of one or more specific gastrointestinal disorders (e.g., crohn's disease, ulcerative colitis, gastrointestinal tumors, pseudomembranous enteritis, gastrointestinal bleeding, enterocutaneous fistula, etc.) 4. diseases with significant correlations to gut microbiota include type 2 diabetes, thyroid disorders, migraines, and autoimmune diseases 5. ex-/intraintestinal organ infection 6. abnormal liver or kidney function 7. faecal occult blood test (+) 8. suffering from chronic pain, restless leg syndrome, obstructive sleep apnea, or thyroid disorders. 9. central nervous system disorders (e.g., epilepsy, parkinson's disease, history of traumatic brain injury, cerebrovascular diseases, etc.) 10. current smokers or alcohol drinkers 11. history of food or antibiotic allergies
procalcitonin to guide obtaining bloodcultures in the icu intensive care infection score

Conditions: Infection

Summary: probic rationale: procalcitonin measurements can reduce the number of blood cultures in the icu. objective: the investigators suggest that pct is a marker for blood stream infection in all patients in the icu in whom attending physicians/ intensivists order blood culturing in the suspicion of microbial infection. the investigators want to demonstrate that its use for guiding blood culturing is cost-effective and safe compared with blood cultures alone. study design: prospective, non- inferiority, multicenter, single-blinded, cluster- randomised cross-over clinical trial. intervention (if applicable): the intensive care units will be allocated into two groups: a control group (blood culture) and the intervention group (procalcitonin). main study parameters/endpoints: safety, expressed as mortality at day 28 and 90, with a mortality difference not exceeding a between groups difference of 10% by non-inferiority analysis. cost-effectiveness, expressed in euro, calculated by deducting costs of procalcitonin testing from saved blood cultures compared with standard treatment spending on blood cultures in the control group. icis rationale: the aim was to evaluate the intensive care infection score (icis) in predicting microbial infection and its sequelae in critically ill patients in whom attending physicians/ intensivists order blood culturing in the suspicion of microbial infection. objective: because of the complexity of the pathophysiology of systemic inflammation it is unlikely that a single parameter will have sufficient diagnostic accuracy for infection. therefore we will study combining parameters producing a diagnostic score. study design: prospective, multicenter, cohort trial. supplement for the control arm of the probic study. intervention (if applicable): blood is drawn for daily routine laboratory measurements and collected in k3edta aliqnots. the icis score is composed of five blood-cell derived parameters which can be extracted using the same aliqnots. main study parameters/endpoints: to develop and evaluate a blood- cell derived score to enable the diagnosis of microbial infection, its likelihood, its invasiveness and severity.


Eligibility criteria:
inclusion criteria: * patients will need to be over the age of 18 and suffering from an assumed infection deemed clinically worthy for blood culturing. exclusion criteria: * uncontrolled malignancy * immunosuppressive or immunostimulatory therapy * neutropenia, defined as leukocyte count less then 0.5x109/l * moribund patients * predetermined illness with an expected death within 24 hours
surgical management of pseudophakic and aphakic retinal detachment; a randomized clinical trial

Conditions: Pseudophakic Retinal Detachment; Aphakic Retinal Detachment

Summary: to compare the visual and anatomical outcomes and complications of four surgical techniques (1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy) for management of pseudophakic and aphakic retinal detachment


Eligibility criteria:
inclusion criteria: * cases of pseudophakic and aphakic retinal detachment with pvr grade a or b exclusion criteria: * pvr grade c * history of surgery for rd * signs of diabetic retinopathy, amd, glaucoma and macular hole * history of ocular trauma * giant retinal tear

Keywords: pseudophakic retinal detachment, aphakic retinal detachment, scleral buckling, primary vitrectomy, proliferative vitreoretinopathy
high impact training to patients with prostate cancer and bone metastases

Conditions: Prostate Cancer

Summary: hip is a randomized controlled trial. the aim is investigate the effect, safety and feasibility of brief, high-impact exercise targeting bones in patients with prostate cancer and bone metastases. furthermore, to investigate the effects of the intervention on bone status (bone mineral density) and body composition, physical function and performance, patient reported quality-of-life outcomes, falls and hospitalizations. the effects of resistance training on the antitumor immunity will be assessed in the peripheral blood and tumor biopsies (hipimmune).

participants assigned to the intervention group will participate in a 32-week, twice-weekly, 30-minute, supervised hip program at the hospital in herlev, denmark. to ensure a safe transition to high-intensity exercise, the first eight weeks of the intervention includes self-bodyweight and low-impact variations with a focus on getting used to use weight training equipment and gradually learning the movement patterns of the hip exercises. all participants should be able to perform the four basic exercises of the intervention within two months. the resistance exercises (deadlift, overhead press, and squats) will be performed in five sets of five repetitions for the remaining intervention period, maintaining an intensity of \> 80% to 85% of 1 repetition maximum (rm). blood samples and tumor biopsies will be taken at different timepoints of the exercise intervention (hipimmune) and analyzed for lymphocyte entitumor responses.

Eligibility criteria:
inclusion criteria: * patients with metastatic hormone sensitive prostate cancer (mhspc) * patients must have bone metastases according to the most recent imaging (bone scan, ct, mri and/or pet) * patients must be treated with androgen deprivation therapy (adt) (orchiectomy, luteinizing hormone-releasing hormone (lhrh) agonist or antagonist treatment) started \< 12 months ago. additional treatment in the mhspc setting, i.e., radiotherapy (rt) of the prostate, novel hormone agents (nha) and/or docetaxel is permitted * patients must have an eastern cooperative oncology group (ecog) performance status score \<2 * patients must be able to speak and read danish and provide a signed informed consent form * patients must be ambulatory without walking aids exclusion criteria: * patients with any physical condition that interferes with the performance of physical exercise training * patients with presence of any musculoskeletal, cardiovascular, or neurologic conditions that may prevent patients from exercising * patients with bone pain requiring opioids * patients with planned or prior palliative radiation therapy to the bone * patients with major surgery within the past 6 months hipimmune: all patients included in hip are eligible for hipimmune

Keywords: bone metastases exercise bone mineral density resistance and impact training antitumor immunity
lenalidomide combined with rituximab as front-line therapy for dlbcl patients aged over 80 years

Conditions: Diffuse Large B Cell Lymphoma; Age Over 80 Years

Summary: about 40% of diffuse large b cell lymphoma relapse or is refractory, age is a prognostic factor of dlbcl, as elderly patients are not capable to received standard treatment, the prognosis of elderly patients is poor especially those aged over 80 years. in this study,we aimed to investigate the safety and efficacy of the combination of lenalidomide and rituximab in elderly patients aged ≥ 80 years with untreated dlbcl.


Eligibility criteria:
inclusion criteria: 1. age≧80 years ; 2. ecog score 0-2； 3. untreated with pathologically conﬁrmed cd20+ dlbcl ; 4. expected life expectancy of ≥ 12 weeks; 5. capable of swallowing tablets; 6. gfr(by cockcroft- gault)≥30 ml/min; 7. can sign written informed consent to participate in the study. exclusion criteria: 1. with cns involvement; 2. with other malignancy (not including adequate-treated non-melanoma cutaneum carcinoma); patients with other cancer but disease-free for ≥5 years can enter this study; 3. with ≥ grade 2 peripheral neurophathy; 4. with cardiopathy including unstable angia or myocardial infarction over the past 8 weeks; 5. received live vaccine within 28 days.; 6. hiv-positive; 7. thrombosis ; 8. gfr\<30 ml/min; 9. other conditions not suitable for rituximab or lenalidomide application.

Keywords: lenalidomide
adoptive transfer of inkt cells for treating patients with relapsed/advanced hcc

Conditions: Hepatocellular Carcinoma

Summary: this study enrolls patients who have relapsed/advanced hepatocellular carcinoma (hcc, bclc stage c). the hcc tumor relapsed or metastasized through the body after standard treatment or the patients cannot receive standard treatment under current conditions. this research study uses special immune system cells called inkt cells, a new experimental treatment. the purpose of this study is to find the biggest dose of inkt cells that is safe and tolerance, to see how long they last in the body, to learn the immunoresponse in the body, to learn the side effects are and to see if the inkt cells will help people with relapsed/advanced hepatocellular carcinoma (hcc).

pbmcs of enrolled patients were collected and then further separated by density gradient centrifugation. after washing three times, the cells were resuspended in serum-free medium with recombinant human il-2 and α-galcer. restimulation with α-galcer-pulsed autologous dcs was done on days 7. after 14 days of cultivation, the inkt cells were harvested, washed thrice, and then resuspended in saline. the frequency of inkt cells before and after cultured in vitro were determined by flow cytometry analysis.

Eligibility criteria:
inclusion criteria: * age 18-80 years. * patients with hepatocellular carcinoma (bclc, stage c) proved by histopathology or proved by ct or mri imaging system, relapsed after previous therapy and no effective therapies known at this time. * life expectancy of ≥ 12 weeks. * wbc\>3.5×10\^9/l, lymph\> 0.8×10\^9/l, hb\>85g/l, plt\>50×10\^9/l, cre\<1.5×the upper limit of normal value. * inkt\>10/ml in peripheral blood mononuclear cell (pbmc). * able to understand and sign the informed consent. exclusion criteria: * any uncontrolled systematic disease: hypertension, heart disease, and et al.; * portal vein tumor thrombus, central nervous system tumor metastasis, or combined with other tumors; * receiving radiochemotherapy, local therapy, or targeting drugs within 4 weeks prior to this treatment; * unstable immune systematic diseases or infectious diseases; * combined with aids or syphilis; * patients with history of stem cell or organ transplantation; * patients with allergic history to related drugs and immunotherapy; * patients with complications associated with liver diseases: moderate or severe pleural effusion, pericardial effusion, ascites, or gastrointestinal hemorrhage; * pregnant or lactating subjects; * unsuitable subjects considered by clinicians.